You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 8,883,155

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,883,155

Title:	Methods for treating hematopoietic malignancies
Abstract:	The present invention relates to methods for treating neoplasias in a mammalian subject. In particular, the invention provides methods for treating lymphomas, including forms of non-Hodgkin lymphoma. In one embodiment, these methods involve reducing tumor necrosis factor signaling.
Inventor(s):	David; Michael (San Diego, CA), Pedersen; Irene Munk (La Jolla, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	12/919,708
Patent Claims:	1. A method of treating non-Hodgkin diffuse large B-cell lymphoma (DLBCL) of an activated B-cell (ABC) subtype in a mammalian subject, comprising administering to the mammalian subject having an ABC-subtype DLBCL an effective amount of adalimumab that reduces expression of inositol polyphosphate-5-phosphatase (SHIP-1) and increases expression of miR-155 in said non-Hodgkin diffuse large B-cell lymphoma (DLBCL) of an activated B-cell (ABC) subtype. 2. A method of treating non-Hodgkin diffuse large B-cell lymphoma (DLBCL) in a human subject, comprising a) detecting increased expression of miR-155 and decreased expression of SHIP-1 in cells of said non-Hodgkin DLBCL in relation to their expression in germinal center B-cell (GCB) subtype DLBCL cells, and b) administering to the human subject an effective amount of adalimumab. 3. The method of claim 2, wherein said DLBCL is an activated B-cell (ABC) subtype DLBCL. 4. A method of treating an activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBLC) in a mammalian subject, comprising administering adalimumab to a mammalian subject having ABC subtype DLBLC in an amount effective to reduce one or more symptoms of said ABC subtype DLBLC. 5. A method of treating an activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBLC) in a mammalian subject, comprising a) obtaining ABC subtype DLBLC tumor cells from the human subject, b) detecting increased expression of miR-155 and decreased expression of SHIP-1 in said tumor cells obtained from the human subject in relation to the expression of miR-155 and SHIP-1 in germinal center B-cell (GBC) subtype DLBCL cells, and c) administering to the human subject having ABC subtype DLBLC tumor cells with increased expression of miR-155 and decreased expression of SHIP-1 adalimumab in an amount effective to reduce one or more symptoms of said ABC subtype DLBLC tumor cells.

Details for Patent 8,883,155

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2028-01-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2028-01-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2028-01-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2028-01-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015	⤷ Try a Trial	2028-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.